News headlines about NanoVibronix (NASDAQ:NAOV) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NanoVibronix earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.619135425488 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

NanoVibronix (NASDAQ NAOV) opened at $4.50 on Monday. The company has a current ratio of 0.30, a quick ratio of 0.20 and a debt-to-equity ratio of -0.32. NanoVibronix has a fifty-two week low of $3.68 and a fifty-two week high of $7.32.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-nanovibronix-naov-stock-price/1757267.html.

About NanoVibronix

NanoVibronix, Inc is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy. The Company’s products include PainShield, WoundShield and UroShield. Its products under development include Renooskin and Endotrachshield. The Company’s principal research and development activities are conducted in Israel, through its subsidiary, NanoVibronix (Israel 2003) Ltd.

Receive News & Ratings for NanoVibronix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoVibronix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.